Clinical Edge Journal Scan

Risk for second primary colorectal, pancreatic, and thyroid cancers elevated in male BC survivors


 

Key clinical point: Male patients who survived breast cancer (BC) were more likely to develop second primary cancers (SPC), such as colorectal, pancreatic, and thyroid cancers.

Major finding: Standardized incidence ratio (SIR) of any SPC was estimated to be 1.27 (95% CI 1.03-1.56), with the risk being elevated in the case of a second primary colorectal cancer (SIR 1.29; 95% CI 1.03-1.61), pancreatic cancer (SIR 1.64; 95% CI 1.05-2.55), and thyroid cancer (SIR 5.58; 95% CI 1.04-30.05).

Study details : Findings are from a meta-analysis of eight retrospective cohort studies including male BC survivors.

Disclosures: This study was funded by the Cancer Research UK Catalyst Award CanGene-CanVar. The authors declared no conflicts of interest.

Source: Allen I et al. Risk of developing a second primary cancer in male breast cancer survivors: A systematic review and meta-analysis. Br J Cancer. 2022;127:1660–1669 (Sep 17). Doi: 10.1038/s41416-022-01940-1

Recommended Reading

Is early-onset cancer an emerging global epidemic?
MDedge Hematology and Oncology
What is known about sexual dysfunction after breast cancer?
MDedge Hematology and Oncology
Reminder that COVID-19 and cancer can be a deadly combo
MDedge Hematology and Oncology
Hair straighteners’ risk too small for docs to advise against their use
MDedge Hematology and Oncology
Switching to fulvestrant + palbociclib benefits ER + HER2− BC patients with rising bESR1mut
MDedge Hematology and Oncology
Metastatic TNBC: Apatinib + vinorelbine shows acceptable efficacy and safety in phase 2
MDedge Hematology and Oncology
HER2+ metastatic BC: Dual blockade with P + T effective and safe in routine clinical practice
MDedge Hematology and Oncology
Differential prognosis of germline BRCA1/2 mutations according to tumor subtypes
MDedge Hematology and Oncology
Re-BCS may not be the best strategy in ipsilateral breast tumor recurrence
MDedge Hematology and Oncology
pT1a-b ER+ BC: Endocrine therapy benefits patients with grade 2-3 tumors
MDedge Hematology and Oncology